Chronic lymphocytic leukaemia+1
Not yet recruitingStudy of nemtabrutinib combined with venetoclax and obinutuzumab in untreated CLL/SLL patients with TP53 alterations
Study of nemtabrutinib combined with venetoclax and obinutuzumab in untreated CLL/SLL patients with TP53 alterations
- Disease:Chronic lymphocytic leukaemiaB-cell small lymphocytic lymphoma
- Substances:NemtabrutinibObinutuzumab+1
France- Participants:18–64 years · 65+ years
- Substances:Nemtabrutinib
- Sponsor:French Innovative Leukemia Organization










